JACC CardioOncology, Journal Year: 2024, Volume and Issue: 6(6), P. 876 - 878
Published: Dec. 1, 2024
Language: Английский
Journal of Hepatology, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 1, 2025
Language: Английский
Citations
2
Archives of Gynecology and Obstetrics, Journal Year: 2025, Volume and Issue: 311(5), P. 1241 - 1247
Published: Jan. 7, 2025
Abstract Purpose Metabolic disease, including obesity and type 2 diabetes, are amongst the most significant health issues facing women of reproductive age. To date, no antenatal weight management tools have reduced risk adverse outcomes for with their offspring, resulting in a shift focus to pre-conception period. Although not yet recognised international guidelines, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) being increasingly used prior conception. Methods A literature search PubMed, Medline, Embase databases identified relevant articles describing use GLP-1 RAs during pregnancy. Papers were selected based on relevance originality, clinical trials, large observational studies meta-analyses preferentially included. Results This narrative review summarises mechanism action effects observed non-pregnant adults. It synthesises available data from human animal regarding safety efficacy pregnancy, consequences inadvertent drug exposure early In considering need balance risks metabolic disease posed by exposure, it highlights areas where further research is needed guide decision-making. Conclusion may role facilitating loss improving However, there currently insufficient evidence demonstrate that this class drugs pregnancy improves outcomes.
Language: Английский
Citations
1
PEDIATRICS, Journal Year: 2025, Volume and Issue: unknown
Published: March 4, 2025
Obesity remains highly prevalent among children in the United States and is associated with an ever-increasing burden of obesity-related diseases. Effective pediatric obesity prevention treatment will require both societal interventions health care system innovation. One recent advancement approval glucagon-like peptide-1 receptor agonists (GLP-1RAs) for use adolescents. GLP-1RAs are notable their effectiveness weight management ability to ameliorate can be important part a comprehensive plan patients seeking care, we review clinician’s considerations effective use. We discuss history pharmacology development GLP-1RAs. indications common adverse reactions. highlight importance mental treatment, focus on disordered eating behaviors intersection pharmacologic obesity. Nutrition issue management, nutritional concerns during GLP-1RA therapy. Finally, inequities obesity, dangers perpetuating these if access biased, opportunities improvement.
Language: Английский
Citations
0
American Journal of Cancer Research, Journal Year: 2025, Volume and Issue: 15(3), P. 946 - 965
Published: Jan. 1, 2025
This study evaluated the effects of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) on glycemic control, islet cell function, insulin resistance in type diabetes mellitus (T2DM) patients with T1-stage renal carcinoma (RCC). A retrospective cohort 175 was divided into a control group receiving SGLT2i monotherapy (n = 84) an observation combination therapy GLP-1RA 91). Propensity score matching (PSM) employed to balance baseline characteristics, resulting 35 per group. After treatment, showed significant improvements fasting plasma glucose (FPG), 2-hour postprandial (2hPG), glycated hemoglobin (HbA1c) compared (P < 0.001). Islet function markers, including HOMA-IR, also improved significantly Renal such as serum creatinine, blood urea nitrogen, urinary albumin excretion rate, were better 0.05). Multivariate analysis identified older age (OR 7.434, P 0.025), higher BMI 6.812, 0.003), high-fat diet 0.044, 0.005) independent risk factors for resistance. The combined use demonstrated superior efficacy improving variability, sensitivity, highlighting its potential effective strategy managing T2DM RCC.
Language: Английский
Citations
0
Canadian Journal of Kidney Health and Disease, Journal Year: 2024, Volume and Issue: 11
Published: Jan. 1, 2024
Diabetes is the most common cause of kidney disease in individuals that receive a transplant, and those without pre-existing diabetes are at greater risk developing following transplant. A class treatment medications called glucagon-like peptide-1 receptor agonists (GLP-1RA) has seen recent widespread use for people with or obesity, efficacy improved glycemic control, weight loss, reduced cardiovascular events. Given these benefits, indications often co-occur transplant recipients, GLP-1RAs warrants consideration this population. Therefore, we sought to review current literature better understand mechanisms action, clinical application, person-centred considerations recipients.
Language: Английский
Citations
2
American Heart Journal Plus Cardiology Research and Practice, Journal Year: 2024, Volume and Issue: 46, P. 100455 - 100455
Published: Sept. 10, 2024
The role of incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP1RAs) and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonists, in the management type 2 diabetes mellitus (T2DM) obesity has been increasingly recognized, along with significant cardiovascular (CV) benefits. Despite clinical efficacy high costs, suboptimal access, limited insurance coverage, therapeutic inertia present substantial barriers to widespread adoption. Overcoming these obstacles is essential for equitable initiation, utilization therapies. Clinicians must make targeted efforts ensure health equity use other advanced
Language: Английский
Citations
0
JACC CardioOncology, Journal Year: 2024, Volume and Issue: 6(6), P. 876 - 878
Published: Dec. 1, 2024
Language: Английский
Citations
0